Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase 2
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 145
- Registration Number
- NCT03586609
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
Phase 2
Active, not recruiting
- Conditions
- Advanced Malignant Solid NeoplasmHematopoietic and Lymphoid System NeoplasmLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 99
- Registration Number
- NCT03583255
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Phase 3
Recruiting
- Conditions
- ENSAT Stage I Adrenal Cortex CarcinomaENSAT Stage II Adrenal Cortex CarcinomaENSAT Stage III Adrenal Cortex Carcinoma
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 240
- Registration Number
- NCT03583710
- Locations
- 🇸🇪
Sahlgrenska University Hospital, Gothenburg, Sweden
🇸🇪Karolinska University Hospital, Stockholm, Sweden
🇸🇪Akademiska Sjukhuset, Uppsala, Sweden
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
Phase 2
Withdrawn
- Conditions
- PSA Level Greater Than TenStage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8
- Interventions
- Procedure: Magnetic Resonance Spectroscopic Imaging
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT03581500
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03581487
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
CD19-Specific T Cells Post AlloSCT
Phase 1
Terminated
- Conditions
- B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A RearrangedRecurrent B Acute Lymphoblastic LeukemiaRecurrent Ph-Like Acute Lymphoblastic LeukemiaRefractory Small Lymphocytic LymphomaRecurrent Non-Hodgkin LymphomaRefractory B Acute Lymphoblastic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Interventions
- Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03579888
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma
Phase 1
Withdrawn
- Conditions
- Recurrent Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaCD19 PositiveRefractory Diffuse Large B-Cell LymphomaMantle Cell LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Follicular Lymphoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationBiological: FilgrastimBiological: RituximabBiological: Umbilical Cord Blood-derived Natural Killer Cells
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03579927
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
Early Phase 1
Active, not recruiting
- Conditions
- Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm
- Interventions
- Other: Questionnaire Administration
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT03579446
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2
Active, not recruiting
- Conditions
- Recurrent Primary Peritoneal CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma
- Interventions
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 96
- Registration Number
- NCT03579316
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
Phase 1
Terminated
- Conditions
- Prognostic Stage IV Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
- Interventions
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT03579472
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon Baines Johnson General Hospital, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath